Pharmaceutical Pricing Policies in Finland – an Example of Uptake of Less Expensive Biologic Medicines
Published 7.8.2025
Abstract
Increasing use and costs of biologic therapies challenge the sustainability of health care systems globally. Finland, with a little less than 6 million citizens and a pharmaceutical expenditure of EUR 3.8 billion, is leading the way toward a higher uptake of less expensive biologic therapies: the steering of prescribing of biologic medicines was introduced in 2023 and pharmacist-led substitution of all other biologic medicines except for short-acting insulins is introduced in stages by 2026. Following chapters shed light on lessons learned so far and provide predictions on future savings and other effects of these measures.
Authors
Kati Sarnola, Hanna Koskinen
Additional Information
- Peer-Reviewed: no.
- Open Access: no.
- Cite as: Sarnola, K., & Koskinen, H. (2025). Pharmaceutical pricing policies in Finland – an example of uptake of less expensive biologic medicines. In Z. Babar (ed.). Formulating and Implementing Pharmaceutical Pricing Policies (pp. 191–207). Academic Press. https://doi.org/10.1016/C2023-0-00807-X
